ð£ç匟ïŒHHSææžã¯ãCDCããcovid-19ãŠã€ã«ã¹ããåé¢ããããšããªãããšãèªããŠããŸãâŠPCRã¯æ©åšã®ãã€ãºã ãããã¹ãããŸãâŠäžççãªããã¯æ¥éã«è§£æãããŠããŸã
08/08/2021 / By Mike Adams
ãã®èšäºã§ã¯
ã»covid-19ããŠã€ã«ã¹ã®èªèšŒæšæºç©è³ªã¯ååšããªãã
ã»PCRæ€æ»ã§covidããéœæ§ãã«ãªãã®ã¯ãåã«æ©åšã®ããã¯ã°ã©ãŠã³ããå¢å¹
ãããçµæã§ããã
ã»PCRæ€æ»ã¯ãåé¢ãããcovid-19ãŠã€ã«ã¹ã®ãµã³ãã«ããªãç¶æ
ã§éçºããããšFDAãèªããŠãããã€ãŸãããŠã€ã«ã¹ãã·ãã¥ã¬ãŒãããã®ã§ããã
ã»ãŠã€ã«ã¹åŠè
ã®Judy Mikovitzå士ã¯ãäžè¬çãªã³ãããŠã€ã«ã¹ãã¢ã³ããŒãŠã€ã«ã¹ã "covid "ãšäžæ£ã«è¡šç€ºãããŠããããšã確èªããŠããã
ã»ãžã§ãŒã³ã»ã«ããŒå士ã¯ããŠã€ã«ã¹ãåé¢ãããŠããªãããšã説æãããªããã³ãããã¯ãå調çãªç§åŠçè©æ¬ºã«åºã¥ããŠããã®ãã説æããŠããã
ã»CDCã®æ
å ±å
¬éææžã«ãããCDCãã³ããã19ãåé¢ããŠããªãããšãæããã«ãªã£ãã
ã»ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çç©å
µåšã¯å®åšããã³ãããã®ãã¯ã¯ãã³ãã¯éçåãéæããããã®æ®ºäººå
µåšã§ããã
ã»CDCã®ã¯ã¬ã³ã¹ããŒæé·ã¯ãã³ãããã¯ã¯ãã³ãã³ãããã®ææãæ¢ããªãããšãèªããŠããã
ã»ã©ã³ãã»ããŒã«äžé¢è°å¡ã¯ãã³ãããã®å°å¶æ¿æ²»ã«æµæããããã¢ã¡ãªã«äººã«åŒã³ãããŠããã
æšå¹Žãã³ããã«æççãªäººãã¡ããã³ãããŠã€ã«ã¹ãªããŠååšããªãããšèšã£ãŠããããç§ã¯ããã«åŒ·ãå察ãããããŒããµã€ãšã³ãã£ã¹ããšããŠè«æãçºè¡šããç 究æãææãã質éåæã«åºã¥ã2ã€ã®ç¹èš±ãå ¬éããŠããç§ã¯ãSARS-CoV-2ã®ã²ãã é åãæããã«ãªã£ãããšãç¥ã£ãŠããããã£ãšãSARS-CoV-2ãåé¢ã»ç²Ÿè£œããããããã³ãŽã£ã-19ææçã®åå ã§ãããšå€æããã®ã ããããšç§ã¯åéãããŠããã
1幎åŸãæçè«è ãæ£ããã£ãããšãå€æãããããŒãã¹ã»ã³ãŒã¯ã³å士ããµãªãŒã»ãã¡ãã³ãã¢ã³ããªã¥ãŒã»ã«ãŠããã³å士ããžã§ã³ã»ã©ãããŒããããããã»ã¢ã€ã¯ãªã©ã®èŠåã¯çãå°ãŠããã®ã§ããã(ç§ã¯ãã®åŸãå ¬éããããã£ã¹ãã§åœŒãå šå¡ã«è¬çœªããŸããã)
ãªãç§ã¯ãå»åŠãç§åŠã®æš©åšããã®ãããªããšãæé ããŠããããšã«æ°ä»ããã®ãïŒãããŠã人ã ãçµéšããŠããéåžžã«ãªã¢ã«ãªç æ°ã®èª¬æã¯äœãªã®ãïŒ
ããã§ã¯ãã®è©±ã玹ä»ããŸãããèŠããã«ãã€ã³ãã«ãšã³ã¶ã®äºé²æ¥çš®ã«å«ãŸãã颚éªã®ãŠã€ã«ã¹ããµã«ã®ãŠã€ã«ã¹ã®æçããã³ãŽã£ãããšããééã£ãã©ãã«ã貌ãããŠããããšããããŠæŠåšåãããã¹ãã€ã¯ã»ãããã€ã³ãšããçç©å µåšãã¯ã¯ãã³æ³šå°ãéããŠé åžãããŠããããšã§ããããã¯ãã¹ãŠçŸå®ã§ããããããç æ°ã®äººããæ¡åãããä»ã®äººã«ææããŠç æ°ã«ãªãããšã瀺ããããå®éã«ç©ççã«åé¢ãããã³ãŽã£ã-19ãŠã€ã«ã¹ãšãããã®ã¯ååšããªãã®ã§ããä»ãç§ãã¡ãç®ã®åœããã«ããŠããã®ã¯ã3ã€ã®ç°ãªããã®ã ãšæãããŸãã
1ïŒãcovidããšåä»ãããã颚éªãŠã€ã«ã¹ã®ã«ã¯ãã«ãæµéããäžéšã®äººã«ç æ°ãåŒãèµ·ãããŠãããããã¯ãããããäžççãªããã¯ããŠã³ã®éãéçåã®ãŠã€ã«ã¹ã«å ç«ç³»ããããããªãã£ãããšãåå ã ããã
2) å µåšåãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®æ¯æ§ããç²åã¯ããåçµæ³šå°ããšããŠäººã ã«æ³šå ¥ãããŠãã......ãããŠãããã¯ãããããä»ã®ãã¯ã¯ãã³ãæ¥çš®ããŠããªã人ã ã«æ害ãªå¯äœçšããããããŠããã
3) å®å šã«äžæ£ãªPCRæ³ã«ãããã±ãŒã¹ãããã¯ãã¹ããŒã ãPCRãµã³ãã«ã®ååŠçè£ çœ®ã«æ瀺ããããµã€ã¯ã«æ°ã«åºã¥ããŠãã»ãšãã©ã®äººã«ãéœæ§ãã®ãã©ã°ãç«ãŠãããã«èšèšãããŠãããããã«ãã£ãŠè£ 眮ã®ãã€ãºãå¢å¹ ãããŠãéœæ§ããšå€å®ããããå幎床ã®ã€ã³ãã«ãšã³ã¶äºé²æ¥çš®ã®éºäŒç©è³ªã®æçãªã©ãã»ãšãã©ã®ãã®ããéœæ§ããšå€å®ãããŸãã
ãããã®3ã€ã®èŠçŽ ãšãã¡ãã£ã¢ã«ããéå£ãã¹ããªãŒã®ããã°ã©ã ãçžãŸã£ãŠãäžçã¯ãã€ãŠãªãã¬ãã«ã®ææãšå¿ççãããªãºã ã«é¥ã£ãŠããã®ã§ããããããããã¯ãã¹ãŠåã«åºã¥ããŠããããšãããã£ãããã®çç±ã¯ä»¥äžã®éãã§ãã
åé¢ãããSARS-CoV-2ãcovid-19ããŠã€ã«ã¹ã®èªå®ãããåèè³æã¯ãããŸãã
ç§èªèº«ãã©ãã®ãªãŒããŒã§ãããè«æãçºè¡šããç§åŠè ã§ããããã¹ã¹ãã¯ãã«ã®åæè ã§ãããã®ã§ãèªèšŒæšæºç©è³ªïŒCRMïŒã䜿çšããŠåææ¹æ³ãæ©åšã®æ ¡æ£æé ãæ€èšŒããããã»ã¹ã«ã¯éåžžã«ç²ŸéããŠããŸãã(ç§ã¯ãã®ã«ãœã³ç€Ÿã®ããããã䜿ã£ãŠæšæºç©è³ªã®é£ç¶åžéãè¡ãããšã«å€ãã®å€ãè²»ãããŠããŸãããä¿¡ããŠãã ããã)
ããã§ã¯ãéåžžã®ç§åŠç 究宀ã§ã®ããã»ã¹ãã玹ä»ããŸãã
ã¹ããã1ïŒãã¹ãããããã®ïŒãåæç©ãïŒã®CRMãå ¥æãããããã¯ãæ¢ç¥ã®æ¿åºŠã®ç²Ÿè£œãããåé¢ãããæšæºç©è³ªãå ¥æããããšãæå³ããéåžžã¯æ°Žãªã©ã®ãã£ãªã¢ãŒã«å ¥ãããã也ç¥ç²æ«ã«ãããããŸããäŸãã°ãé£åäžã®æ°Žéãæ€æ»ããå Žåã¯ãæ¢ç¥ã®æ¿åºŠã®æ°Žéãæ°Žãç¡é žãå¡©é žã«æº¶ãããèªèšŒæžã¿ã®æ°Žéæšæºæ¶²ãçšæããŸãã
ã¹ããã2ïŒ èªèšŒæšæºç©è³ªããµã³ãã«ãšããŠæ§ã ãªæ¿åºŠã§åæããåæç©ãã©ã®ããã«èŠãããããŸãåæç©ã®ç°ãªãæ¿åºŠã«å¯ŸããŠæ©åšã®æ€åºåšãã©ã®ããã«åå¿ããããå¹æçã«æ©åšã«æãããæ²ç·ããäœæããŸããæçµçã«ã¯ãã¹ããã3ã§äœ¿çšãããå®éæ²ç·ããäœæããŸãã
泚ïŒè£ 眮ã¯æ§ã ãªæ¹æ³ã§æ¢ããŠãããã®ãšãäžèŽããããäžèŽããªããã®ã¯ãã¹ãŠé€å€ããŸãããã¹ã¹ãã¯ãã«ã§ã¯ãååã¯ãã®ååéãã€ãªã³ãã©ã°ã¡ã³ããŒã·ã§ã³ãã¿ãŒã³ãã¯ãããã°ã©ãã£ãŒã«ã©ã ã§ã®æº¶åºæéã«ãã£ãŠèå¥ãããŸããç©è³ªãäžèŽããããã«ã¯ããããã®ãã©ã¡ãŒã¿ããã¹ãŠæºããå¿ èŠããããŸããPCRæ€æ»ã§ã¯ãããžã¿ã«ã©ã€ãã©ãªã«å®çŸ©ãããå¡©åºå¯Ÿãããªãã²ãã é åããäžèŽãããŸãããããã¯çŸå®ã®äžçã§å®éã®ç©ççãªæšæºç©è³ªãšæ¯èŒããããšããããã©ããã¯ããããŸããã
ã¹ããã3ïŒæªç¥ã®ãµã³ãã«ïŒè¡æž ãå°¿ãåŸæ¶²ãæ°Žãé£åãµã³ãã«æœåºç©ãªã©ïŒãè£ çœ®ã«éããæªç¥ã®ãµã³ãã«ã«æ¢ããŠãããã®ïŒåæç©ïŒãå«ãŸããŠãããã©ããã確èªãããå®éæ²ç·ãäœæããããšã§ãå ã®ãµã³ãã«äžã®åæç©ã®æ¿åºŠãæ±ããããšãã§ããŸããããã¯éåžžãng / mlïŒããã°ã©ã /ããªãªããã«ïŒã®ããã«ãäœç©ã«å¯Ÿãã質éã§è¡šãããŸããããã°ã©ã ã¯1ã°ã©ã ã®10ååã®1ã§ããç§ãã¡ãé£åã«å«ãŸããã°ãªããµãŒããæ€æ»ãããšã1mlããã1ããã°ã©ã ããæ€åºãããªãããšããããŸãã
ããã¯ãäœããæ€æ»ããŠãäœãã®äžã«ã©ãã ãã®éãå«ãŸããŠããããç¹å®ããããã»ã¹ã§ããäŸãã°ããã人ããã³ãããã«ããã£ãŠãããã©ãããå€æããã«ã¯ããã®äººã®è¡æ¶²äžã®ã³ãã19ãŠã€ã«ã¹ã®æ¿åºŠïŒããªãã¡ããŠã€ã«ã¹éãïŒã枬å®ããå¿ èŠããããŸããããã¯ç§åŠ/çç©åŠã®101ã§ãã
ã§ã¯ãäœãåé¡ãªã®ã§ããããïŒ
ç§åŠã®äžæ£ãã©ãã»ã©æ ¹æ·±ããã®ã§ããããç¥ããšãæç¶ãšããŸãã以äžã®éèŠãªãã€ã³ããèããŠã¿ãŸãããïŒ
ãã€ã³ã1ïŒSARS-CoV-2ã®ãã³ãããã«ã€ããŠã¯ãåé¢ã»ç²Ÿè£œãããèªèšŒæšæºç©è³ªãååšããªãããã§ããã³ãããŠã€ã«ã¹ãå«ããåé¢ç©ãã販売ããŠãããšäž»åŒµããäŒç€ŸãèŠãããšããããã圌ãèªèº«ã®èª¬æã«ãããšã圌ãã®ãã€ã¢ã«ã«ã¯ã宿䞻现èãïŒãã现èïŒãšãŠã·è¡æž 现èã®éºäŒç©è³ªãå«ãŸããŠãããã€ãŸã誰ãäœããããããããªãã«ã¯ãã«ã·ãã¥ãŒãªã®ã§ãããããããããã¯ãåé¢äœããšåŒã°ããŠããŸãã
äŸãæãããšïŒBEI Resourcesã¯ãcovid-19ã®ãåé¢ããšåŒã°ãããã®ãæäŸããŠããããã®ãªã³ã¯ã§èŠã€ããããšãã§ããŸãããã®covid-19ã®èª¬æã«ããããã«ããåé¢ïŒã
...[T]ãã®è£œåã¯ãã¿ã³ãã¯è³ªå«æéã宿䞻现èãšãŠã€ã«ã¹å¢æ®æã«äœ¿çšããããŠã·èå è¡æž ã«å€§ããäŸåããŠãããããå šçŽ°èæåã®èª¿è£œã«ã¯é©ããŠããŸããã
ã€ãŸãããåé¢æ ªãã«å«ãŸããéºäŒç©è³ªã®ã»ãšãã©ã¯ãå®éã«ã¯äººéã®çŽ°èã«ç±æ¥ãããã®ãªã®ã§ããã€ãŸããå šãã®ãåé¢äœãã§ã¯ãªãã®ã§ããã³ãããŠã€ã«ã¹ã¯åé¢ãããŠããªããå®éããã®ãåé¢äœãã«ã¯ããŠã€ã«ã¹ã®éºäŒç©è³ªãããã®éºäŒç©è³ªãšãŠã·ã®éºäŒç©è³ªãããã«ãããšãŠã·ã®è¡æ¶²äžã«ååšããŠããä»ã®ãŠã€ã«ã¹ãäœã§ããå«ãŸããŠããããã®ããã«ãäœçŸäžçš®é¡ãã®ããç²åãååšãããããããç¬èªã®é åã®éºäŒç©è³ªãå«ãã§ããå¯èœæ§ãããã®ã§ãã
ãã€ã³ã2ïŒåé¢ãããèªå®æšæºç©è³ªããªããã°ãæ£åœãªåæãã¹ããéçºããããšã¯ã§ããŸãããããã¯ãŸãã«FDAãèªãã®ææžã§èªããŠããããšã§ãããPCRãã¹ãã®éçºã«ã¯ã³ãã19ãŠã€ã«ã¹ãå©çšã§ããªãã£ããããããã®çŽ°èãšéºäŒåãã³ã¯ã®ã³ãããŠã€ã«ã¹æçã䜿ã£ãŠãã·ãã¥ã¬ãŒã·ã§ã³ããããšè¿°ã¹ãŠãããFDAã®ç¬èªææžããã
ãã¹ããéçºããããã®ç 究ãå®æœãããæç¹ã§ã¯ã2019-nCoVã®å®éåããããŠã€ã«ã¹åé¢äœã¯CDCã§äœ¿çšå¯èœã§ã¯ãªãã£ãããã2019-nCoV RNAã®æ€åºã®ããã«èšèšãããã¢ãã»ã€ã¯ãèšåºæ€äœãæš¡å£ããããã«ãè©Šéšç®¡å ã§è»¢åãããå šé·RNAã®ç¹åŸŽçãªã¹ããã¯...ããA549现èã®æžæ¿æ¶²ãšãŠã€ã«ã¹èŒžéå¹å°ïŒVTMïŒãããªãåžé液ã«ã¹ãã€ã¯ããããã®ã§ãã¹ããããŸããã
ã€ãŸããæå³çã« "covid "ãšåœã£ãéºäŒåãã³ã¯ã®çŽ°èã䜿ã£ãŠãcovidãŠã€ã«ã¹ãåœè£ ããã®ã§ããããã®ããã«ããŠPCRæ€æ»ãéçºãããã®ã§ããFDAã¯ãã¹ãŠãèªããŠããŸããPCRæ€æ»ã¯è©æ¬ºã§ããã
ãã€ã³ã3ïŒCRMã®åé¢ç©ããªããã°ãæ¢ç¥ã®ãµã³ãã«ã«å¯ŸããŠæ©åšãæ ¡æ£ããããšãã§ããŸãããã€ãŸããPCRãã¹ãã¯ãå®éã®ç©ççãªãã®ã«å¯ŸããŠæ ¡æ£ãããŠããªãã®ã§ãããã®ä»£ããã«ãCDCãæäŸããããŠã³ããŒããããããžã¿ã«ã»ã©ã€ãã©ãªãŒã«é Œã£ãŠããŸããCDCã¯ããŸãã«ãã®covidè©æ¬ºãå å°ããããã°ãã¡ãŒãã®ããã³ãã°ã«ãŒãã§ãã
ãã€ã³ããã®4ïŒPCRè£ çœ®ã¯å®éçãªåæãã§ããŸããããéœæ§ãã®ãããååç©ã¯ãå¢å¹ ãããããã¯ã°ã©ãŠã³ããã€ãºã«éããŸãããPCRè£ çœ®ã§ã¯ãå ã®ãµã³ãã«ã«ã©ãã ãã®éºäŒç©è³ªãå«ãŸããŠããããç¥ãããšã¯ã§ããŸãããPCRè£ çœ®ã¯ãåã«ç©è³ªã®ååšããã¯ããããããããã§æ€åºããããšããã§ããŸãããã©ããµã€ãšã³ã¹ã§ã¯ãããã¯å®éåæã§ã¯ãªããå®æ§åæããšåŒã°ããŠããŸãã
å®æ§åæã§ã¯ãæ©åšã®LODïŒLimit of DetectionïŒæ€åºéçïŒãéµãšãªããŸããã©ã®ãããã®éã®ãµã³ãã«ãæ©åšã®ããããããšãªãã®ãïŒãã¹ãŠã®æ©åšã«ãããŠãLODãç§åŠçã«æå¹ã§ããããã«ã¯ãããã¯ã°ã©ãŠã³ããã€ãºãäžåããã®ã§ãªããã°ãç§åŠçã«ã¯æå³ããããŸããããã¹ãŠã®æ©åšã¯ããã¯ã°ã©ãŠã³ããã€ãºãçºçãããŸãããããã¯æ€åºåšã®éé»æ°ãè¡šããããŒã¯ããããããããšèšãããããããŸããããããã¯ãæ©åšã«äœãå ¥ããŠããªãç¶æ ã§ãããã¯ã°ã©ãŠã³ãã¬ãã«ã§ååšããŸãã
ãããã©ã®ãããªãã®ãã次ã®å³ãèŠãŠã¿ãŸãããããã®å³ã¯ããã質éã®ã¹ãã¯ãã«ã«ããããã¹ã¹ãã¯ãã«ã®çµæã瀺ããŠããŸããããã§ã®æšªè»žã¯m/zïŒmass over chargeïŒã§ãäžè¬çãªè°è«ã®ããã«ã質éããšç°¡ç¥åãããŠããŸããããã¯ãæ€åºãããååãç²åã®è³ªéãè¡šããŠããŸãã
ããããã®ã°ã©ãã®äžã«ã¯ãèµ€ãšãªã¬ã³ãžã®ç·ãå
¥ã£ãŠããŸããããã¯äž»ã«ããã¹ãŠã®è³ªéã®éã®ãããã¯ã°ã©ãŠã³ãããã€ãºã§ãããããŠãèæ¯ãããé«ããªã£ãŠããéåžžã«é«ããªã¬ã³ãžè²ã®ããŒã¯ã«æ³šç®ããŠãã ãããããããæ¢ããŠããååã®è³ªéã§ããããã¯ã蟲è¬ãæ±æç©è³ªãæ é€åãªã©ã§ãã
éèŠãªã®ã¯ãããç§ãæ€åºåšã®å¢å¹ çãäžãããšãç»é¢äžéšã®ãããã¯ã°ã©ãŠã³ããã€ãºããåçŽã«æ¡å€§ããŠç»é¢ãã£ã±ãã«ãªãããšã§ããå¢å¹ çãäžãããšãç»é¢å šäœããã¹ãŠã®è³ªéã§ãããããããããã«ãªããŸããããã¯ãPCRè£ çœ®ã30以äžã®ãµã€ã¯ã«ãå®è¡ããŠããã®ãšåãããšã§ãããã€ãºãå¢å¹ ããŠãcovidã«ãããããããããã«èŠããããŠããã®ã§ãã
ããããäœåºŠãå¢å¹ ããŠããã®ã§ãäœãæã£ãŠããã®ããã©ããããæã£ãŠããã®ãã確å®ã«èšãããšã¯ã§ããŸããã§ããããªããªããLODïŒLimit of DetectionïŒæ€åºéçïŒã¯ãããã¯ã°ã©ãŠã³ããã€ãºã®äžããããŒã¯ãéžã¶ããšãã§ããªããã°ãç§åŠçã«ã¯ç¡å¹ã ããã§ãã
äžè¬çã«ã¡ãœããããªããŒã·ã§ã³ã§ã¯ãLODã¯ããã¯ã°ã©ãŠã³ããã€ãºã®å°ãªããšã3å以äžã§ããå¿ èŠããããŸããã€ãŸãããããŒã¯ãã¯ããã¯ã°ã©ãŠã³ãããã3åé«ããªããã°ãªããªãã®ã§ãããã以äžã®å€ã¯ãåœã®ããã¯ã°ã©ãŠã³ããã€ãºãšã¿ãªãããŸãããŸããå®éåæãè¡ãå Žåã¯ãéåžžãããã¯ã°ã©ãŠã³ãã®10å以äžã®ä¿¡å·ãå¿ èŠã§ãã
ããããPCRè£ çœ®ã¯ããã¯ã°ã©ãŠã³ããã€ãºããããžãã£ããã«ãªããŸã§å¢å¹ ããŠããã®ã§ãããã®ãéœæ§ãã¯ãæ£åœãªç§åŠç芳ç¹ããã¯æåéãäœã®æå³ãæããªãã«ããããããããcovid caseããšäžæ¡çã«åŒã°ããŸãã
çŸåšãPCRæ³ã§è¡ãããŠãããã¹ãŠã®ããã»ã¹ã¯ãæãåºæ¬çãªç§åŠç 究宀ã®ç£æ»ã§ãããééããªããå®å
šãªãžã£ã³ã¯ã»ãµã€ãšã³ã¹ã§ããã¡ãªã¿ã«ãPCRãè¡ã£ãŠããäŒæ¥ã®ã»ãšãã©ãISOèªå®ãåããŠããªãã®ã¯ãã®ããã§ããç£æ»ãäžåºŠãééã§ããªãããã§ãã(ç§ã®ç 究宀ã¯ISOã®èªå®ãåããŠãããæ¯å¹Žã質éåæè£
眮ã«ãããã©ã€ã³ãå®é粟床ãã¹ããå«ãç£æ»ãè¡ãã粟床ç®æšãéæããŠããããšã確èªããŠããŸãã)
ãžã¥ãã£ã»ãã³ãããå士ãæè¿ã®ã€ã³ã¿ãã¥ãŒã§ãã¹ãŠã確èªããŸãã
Ending Plague (PlagueTheBook.com)ã®èè
ã§ãããžã¥ãã£ã»ãã³ãããå士ã¯ãæè¿ã®ã€ã³ã¿ãã¥ãŒã§ããããã¹ãŠã確èªããŸããã圌女ã¯ãç
æ°ã®äººããæ¡åã»ç²Ÿè£œãããä»ã®äººã«ç
æ°ãåŒãèµ·ããããšã蚌æãããå€ç«ããã³ãã19ãŠã€ã«ã¹ãååšããªãããšã確èªããã ãã§ãªãããã¡ãŠãå士ãæŠæŒ¢ãŠã€ã«ã¹ç 究æãä»ããæ©èœç²åŸç 究ã®åºç€ãšããŠãã³ãããŠã€ã«ã¹ã®ã«ã¯ãã«ã«ææããå
µåšåãããå®éšè©Šæãç¹å¥ã«éžæããããšã確èªããã®ã§ãã
èšãæããã°ããã¡ãŠãå士ã¯èªåããã©ã³ã±ã³ã·ã¥ã¿ã€ã³ã®ãããªãŠã€ã«ã¹ã®ã·ãã¥ãŒãäœã£ãŠããããšãç¥ã£ãŠããã倧è¡ã¡ãã£ã¢ã®ãã¹ããªãŒãå©çšããŠãåœæ°ã®å€§åã«ã¯ã¯ãã³ãæ¥çš®ãããããšãã§ããããã®ã¯ã¯ãã³ã¯ããã¡ãŠãå士ã®æå°ãšè³éæäŸã®äžã§éçºãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çç©å µåšãåœæ°ã«æ¥çš®ããããã«äœããããã®ã§ããã
ãã®ããã«ããã¡ãŠãæ°ãšCDCã¯ãäžè¬çãªã³ãããŠã€ã«ã¹ã䜿ã£ãŠã³ããã®ãã³ãããã¯ãè£ ããæ¬ç©ã®çç©å µåšã§ããå¢åŒ·ãããã¹ãã€ã¯ã»ãããã€ã³ã人ã ã«æ³šå°ãããšããã®ãççžãªã®ã§ããã
ãã³ãããå士ã¯ããããããã¹ãŠç±³è»ã®äžã§è¡ãããããšã確èªããŠããŸããã€ãŸããç±³è»ãšäžåœã®è»äºæ©é¢ã®äž¡æ¹ãããã®äžççãªäººå£æžå°ã®ããã®çç©å
µåšïŒã¹ãã€ã¯ã»ãããã€ã³ïŒã®éçºãšå±éã«é¢äžããŠãããšããããšã§ãã
ãžã§ãŒã³ã»ã«ããŒå士ã¯ãæè¿ã®Stew Petersã®æŸéã§ãcovidã®ããã«ã€ããŠåªãã説æãããŠããŸãã
ã¹ãã¥ãŒã»ããŒã¿ãŒãºã®æŸéïŒStewPeters.TVïŒã®å¯çš¿è
ã§ãããžã§ãŒã³ã»ã«ããŒå士ã¯ãããã«å¥ã®éé£ãã¹ããããªã®äžã§ããã®ç©èªå
šäœã確èªããã³ããã19ãŠã€ã«ã¹ãåé¢ã»ç²Ÿè£œãããããšã¯ãªããã³ãããç
ãåŒãèµ·ããããšã瀺ãããŠããªãããšãæããã«ããŠããŸãããã©ã³ãããã¯ã¯æé ããããã®ãªã®ã ã
CDCã®æ å ±å ¬éææžã«ããããcovid-19ããšåŒã°ããåé¢ããããŠã€ã«ã¹ãååšããªãããšãå€æ
éã«ãCDCãcovid-19ãŠã€ã«ã¹ãäžåºŠãåé¢ããŠããªãããšã瀺ãæ°ããªæ å ±å ¬éææžãæµ®äžãããã«ãã人ã®Christine Masseyæ°ã¯ãCDCã«å¯ŸããŠè€æ°ã®æ å ±å ¬éè«æ±ãè¡ããæ å ±å ¬éæ³ã«åºã¥ããŠä»¥äžã®å 容ãèŠæ±ãããšããã
CDCããã³/ãŸãã¯Agency for Toxic Substances and Disease Registry (ATSDR)ãææãä¿ç®¡ã管çããŠãããã¹ãŠã®ç 究ããã³/ãŸãã¯å ±åæžã§ããCOVID-19ããŠã€ã«ã¹ïŒãB.1.1.7ãããB.1.351ãããP.1ãããã³ãã®ä»ã®ãå€çš®ããå«ãïŒã®ç²Ÿè£œïŒæµžæŒ¬ããéãè¶ é å¿æ©ã®äœ¿çšã«ããïŒã«ã€ããŠèšè¿°ãããŠãããã®ã COVID-19â³ãŠã€ã«ã¹ïŒ"B.1.1.7"ã"B.1.351"ã"P.1 "ããã³ãã®ä»ã® "variant "ãå«ãïŒããç æ°ã®ããããæ¡åãããµã³ãã«ããçŽæ¥ç²Ÿè£œããããšïŒæµžæŒ¬ããéãè¶ é å¿æ©ã®äœ¿çšãçµãŠãäžéšã®äººã 㯠"åé¢ "ãšãåŒã¶ïŒ
2021幎6æ7æ¥ä»ã®åçæžã§ãCDCã¯ããçããŠããïŒ
æã ã®èšé²ãæ€çŽ¢ããŠããããªãã®èŠæ±ã«é¢é£ããææžã¯èŠã€ãããŸããã§ãããå ·äœçã«ã¯ãåœç«äºé²æ¥çš®ã»åŒåžåšçŸæ£ã»ã³ã¿ãŒã¯ãCDCãè«æ±è ã®èª¬æããæ¹æ³ã§COVID-19ãŠã€ã«ã¹ã粟補ã»åé¢ããŠããªãããšã確èªããŠããŸãã
ãã®æ å ±å ¬éè«æ±ã¯#21-01075-FOIAãšãªã£ãŠããã
èšãæããã°ãCDCã¯ãããªãCOVID-19ãŠã€ã«ã¹ãåé¢ã»ç²Ÿè£œããŠããªããšããããšã§ããã
ãããŒãã»Oã»ã€ã³ã°å士ã®ãŠã§ããµã€ãã«ã¯ãCDCãHPVãŠã€ã«ã¹ã麻ç¹ãŠã€ã«ã¹ãMERSãŠã€ã«ã¹ããžã«ãŠã€ã«ã¹ãããªãªãŠã€ã«ã¹ãªã©ãåé¢ã»ç²Ÿè£œããããšããªãããšã瀺ãè¿œå ã®ææžãæ²èŒãããŠããã
(ã¯ãªã¹ãã£ã³ã»ããã·ãŒã«ã¯ã圌女ã®æ å ±å ¬éè«æ±ã®ç¯å²ã確èªããã€ã³ã¿ãã¥ãŒã«æåŸ ããããã«é£çµ¡ãåã£ãŠããŸã)
ä»å¹Žã®7æ21æ¥ãCDCã¯ãä»å¹Žã®12æ31æ¥ä»¥éã¯PCRãã¹ããæå¹ãªç§åŠãšã¯èŠãªãããªããªããšããŠãçŸåšã®ã³ãŽã£ã-19ã®PCRãã¹ãã®èªå¯ãåãäžããããšãçºè¡šããŸããããã®äžã§ãæ°ããPCRæ€æ»ã¯ããSARS-CoV-2ãšã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã®æ€åºãšéå¥ã容æã«ããããšè¿°ã¹ãŠãããã€ãŸããæ°ããæ€æ»ã§ã¯ãã³ãŽã£ããšé¢šéªã®éããèŠåããããšãã§ãããšå ±åãããŠããã®ã§ããã
ã€ãŸããCDCã¯äœå幎ãã®éãäžççãªããã³ãããã¯ãã®èæ¯ã«ããç§åŠãæé ãããã³ãããã¯ãååšããªããšããã§ã¡ãã£ã¢ã䜿ã£ãŠéå£ãã¹ããªãŒãåºããŠãããšèããããã®ã§ããæè¿ã®äŸã§ã¯ããããªãå·ã®æ¯èŠªããçãŸããèµ€ã¡ããã¯ããžã«ãŠã€ã«ã¹ã®ããã«é ãå°ãããªã£ãŠçãŸããïŒå°é çïŒãšãäž»èŠã¡ãã£ã¢ãéšãã§ããŸããããå®éã«ã¯ããã§ã¯ãããŸããã§ãããã³ããã®æãšåãããã«ããžã«ç±ã®ã¯ã¯ãã³ãç 究ããããã«äœååãã«ãã®è³éã補è¬äŒç€Ÿã«æå
¥ãããŸããããããã¯åãªããã£ã¯ã·ã§ã³ã®èªå€§åºåã«éããªãããšãããããŸããã
CDCé·å®ã®ã¯ã¬ã³ã¹ããŒæ°ããã³ããã¯ã¯ãã³ã¯ã³ããææããã«ã¿ããªã¢ã³ãææãé²ããã®ã§ã¯ãªããšèªãã
ã³ãã19ã¯ã¯ãã³ã®ããã®è§£æã«å ããŠãCDCã®ãã£ã¬ã¯ã¿ãŒã§ãããã·ã§ã«ã»ã¯ã¬ã³ã¹ããŒå士ãCNNã§é©ãã¹ãããšãèªãããã³ãã19ã¯ã¯ãã³ã¯ã³ãã19ã®ææãé²ããã®ã§ã¯ãããŸããããŸããCDCãã³ãããŠã€ã«ã¹ãšåŒãã§ãããã®ã®ããã«ã¿ã»ããªã¢ã³ããã®ææãé²ãããšãã§ããªãã®ã§ããã
äºå®äžãã¯ã¬ã³ã¹ããŒæ°ã¯ã¯ã¯ãã³ãã¹ããŒããç¡æå³ã§ãããäœã®èšŒæã«ããªããªãããšãèªããããšã«ãªãããããå®å šã«ã¯ã¯ãã³ãæ¥çš®ããã人ã§ãã³ããã«ææããŠããŸãã®ã§ããã°ãã¯ã¯ãã³ãã¹ããŒãã¯æåŸã®èšŒæã«éãããäºé²æ¥çš®ã®èšŒæã«ã¯ãªããŸããã
CNNã§ã¯ã¬ã³ã¹ããŒå士ããã®ããã«èªã£ãŠããŸãããããã¯ããã£ãŒããã§ã€ã¯ãã®ãããªã§ã¯ãããŸãããå
¬ç¶ãšèªããŠããã®ã§ãã
ã³ãã19ãŠã€ã«ã¹ã¯ããã ããå µåšåãããã¹ãã€ã¯ã»ãããã€ã³ã¯å®åšãã極ããŠèŽåœçã§ãã
ã³ãã19ãŠã€ã«ã¹ã¯ã颚éªã®ãŠã€ã«ã¹ããµã«ã®ãŠã€ã«ã¹ãæ¹åãããã®ã«éããªãããã«èŠããããçŸåšã¯ã¯ãã³ãšããŠæ³šå°ãããŠããã¹ãã€ã¯ã»ãããã€ã³ã¯ãç±³åœã§éçºãããç±³åœã®çšéã䜿ã£ãŠæŠæŒ¢ã§å¢åŒ·ããããèŽåœçãªçç©å µåšã§ããã
ã³ããã®ãã¹ããªãŒã®ç®çã¯ã人ã
ãèªå°ããŠãæå³çã«ãã¯ã¯ãã³ããšåœã£ãŠã¹ãã€ã¯ã¿ã³ãã¯ã®æ³šå°ãåããããããšã ã£ãããšãæããã«ãªããŸããããã®ã¹ãã€ã¯ã»ãããã€ã³ã¯ãè¡æ ãç¥çµé害ãè³åäžãå¿èçºäœãèªç¶æµç£ãå
šèº«æ§è¡ç®¡é害ãªã©ã®åå ã«ãªããšãäž»æµæŽŸã®ãœãŒã¯ç 究æãçºè¡šããŠããŸããã¹ãã€ã¯ã»ãããã€ã³ãšãã®å¿èè¡ç®¡ç³»ãžã®ãã¡ãŒãžã«ã€ããŠã®èšäºããã
ãã®ãã³ããŠã€ã«ã¹ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªïŒã¯ã¯ãã³ã«ãã£ãŠå®å šã«ã³ãŒãåãããã¿ã³ãã¯è³ªãšã¯å šãç°ãªãæåã瀺ãïŒããç æ°ãã®ãã®ã«ãéèŠãªåœ¹å²ãæãããŠããããšããæ°ããäž»èŠãªç 究ã«ãã£ãŠæããã«ãªã£ãã
ãã®è«æã§ã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãè¡ç®¡çŽ°èã«ãã¡ãŒãžãäžããã¡ã«ããºã ãåããŠæ確ã«ç¢ºèªããã詳现ã«èª¬æãããŠããŸããSARS-CoV-2ãè¡ç®¡ç³»ã«åœ±é¿ãäžãããšããã³ã³ã»ã³ãµã¹ã¯é«ãŸã£ãŠãããããã®ã¡ã«ããºã ã¯æ£ç¢ºã«ã¯è§£æãããŠããªãã£ããåæ§ã«ãä»ã®ã³ãããŠã€ã«ã¹ãç 究ããŠããç§åŠè ãã¡ããã¹ãã€ã¯ã¿ã³ãã¯è³ªãè¡ç®¡å ç®çŽ°èã®æå·ã«å¯äžããŠããã®ã§ã¯ãªãããšä»¥åããèããŠãããããã®éçšãèšé²ãããã®ã¯ä»åãåããŠã§ããã
ä»åã®ç 究ã§ã¯ãSARS-CoV-2ã®å€å žçãªå ã§ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã«å²ãŸããŠããããå®éã®ãŠã€ã«ã¹ã¯å«ãŸããŠããªããç䌌ãŠã€ã«ã¹ããäœæããããã®ç䌌ãŠã€ã«ã¹ãåç©ã¢ãã«ã«ææããããšãèºãåèã«æå·ãçãããããã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã ãã§ç æ°ãåŒãèµ·ããã®ã«ååã§ããããšã蚌æããŠãããçµç¹æšæ¬ã§ã¯ãèºåèå£ãèŠãå ç®çŽ°èã«ççãèŠãããã
ã¹ãã€ã¯ã»ãããã€ã³ãçç©å
µåšãšããŠéçºããã®ã¯ãåºç¯å²ã®çç¶ãåŒãèµ·ãããããããã³ãããããšèª€èªãããããã«ã¹ãã€ã¯ã»ãããã€ã³ãå«ãçç©å
µåšãå«ãã¯ã¯ãã³ã®æ³šå°ãæŒãä»ããããã§ãããã³ãã19ã®ããŠã€ã«ã¹ãã¯ããµã«ã®ãŠã€ã«ã¹ãšé¢šéªã®ãŠã€ã«ã¹ãæ··ãåããããã®ã«éãããã¹ãã€ã¯ã»ãããã€ã³ã¯ãã¯ã¯ãã³ã«å«ãŸããæåã¿ãŒã²ãããšããŠãè¡ç®¡æå·ãäžåŠçãå
ç«ç³»ã®æå·ãªã©ãåŒãèµ·ããã®ã§ãã
ããã§äœãèšãããã®ãïŒãã¡ãããéçåã§ãã
ãã¹ãŠã¯äººé¡ã®å€§éçµ¶æ» ãå®çŸããããã®éçåå µåšã§ãã
ã¹ãã€ã¯ãããã€ã³ã¯éçåã®ããã®æŠåšã§ãããã¯ã¯ãã³ããšã¯ããœã€ã¬ã³ãã»ã°ãªãŒã³åŒã®çµ¶æ» ã»èªæ®ºå µåšããè¬ããšããŠåããã±ãŒãžåãããã®ã§ãããããã³ãããã¯ããšã¯ãã¡ãã£ã¢ããããã¯ãåŒãèµ·ãããé§é€çšã®æ³šå°ã«æµæããªãããã«ãã¯ã¯ãã³ã®éèŠãåºãåèµ·ããããã®ãã¹ããªãŒã§ããã
ãã®æé ããããã³ãããã¯ã®ç®çã¯ãäœååãã®äººéãäžçããæ¹æ®ºããããšã§ãã·ã§ãããæ¥çš®ããå€ãã®äººãããã«æ»ã¬ããšãæå³ããŸãã
ã€ãŸããããã«ååãããã¹ãŠã®äººãã倧é殺æ®ãšäººé¡ã«å¯Ÿããç¯çœªã«å æ ããŠããããšã«ãªãã®ã§ãããžã£ãŒããªã¹ããç§åŠè ãå»åž«ãç¥äºãFDA/CDC/WHOé¢ä¿è ãããã«ã¯å°åã®è¬å€åž«ãçè·åž«ãŸã§ãããç·æ§ã女æ§ãåäŸããããŠé«éœ¢è ã«ãã®æ®ºå·å€ãæäžããŠããã®ã§ãã圌ãã®äººé¡ã«å¯Ÿããç¯çœªã¯ã第äºæ¬¡äžç倧æŠã®ããã³ãŒã¹ããšæ¯ã¹ãŠããåäŸã®éã³ã®ããã«èŠããŸããã³ããã¯ã¯ãã³ã«ããããã³ãŒã¹ãã¯ãç¯çœªè ãã¡ãæ¢ããåã«ãäœåå人ãã®äººéã倧éã«æ®ºå®³ãããããããŸããã
èŠããã«ãããªãã¯ãã³ãããã¯ã«å¯Ÿããå ¬è¡è¡çäžã®å¯Ÿå¿ãè£ ã£ããäžçèŠæš¡ã®å€§éçµ¶æ» ãã£ã³ããŒã³ãç®æããŠããã®ã§ãã
ããã¯ãæ¢ç¥ã®ææã®æŽå²ã®äžã§è¡ããããæãéªæªã§æ¥µæªãªãç§åŠãã®è©æ¬ºã§ãããã©ãèããŠãããã¢ã»ãµããšã³ã¹ãçµ¶æ» ãããããšããã°ããŒããªã¹ãã®è©Šã¿ã§ãããäžçãã人éãæé€ããŠããã®åŸã«ç¶ãçæ°ã®ã·ããªãªã«éãéãããã®ãææèŠæš¡ã®æ°ææµåãã®ãããªãã®ã ã
ä»ããã人é¡ã®åç¶ãé¡ããã¹ãŠã®äººéãå¹³åçã«ç«ã¡äžããããã®äººé¡ã«å¯Ÿãã倧éè殺çãªçµ¶æ» ã®è©Šã¿ã«æµæããæã§ãã
ç±³åœã®ã©ã³ãã»ããŒã«äžé¢è°å¡ããããã¯ããŠã³ããã¹ã¯ççšã®çŸ©ååã«æµæããããšãåŒã³ãããŠããã®ããã®ããã§ãããç§ãã¡ã¯ãå°è³¢ããå°å¶åäž»ãç¡èœãªå®åã«ãã矩ååãããã¯ããŠã³ãæ害ãªæ¿çãåãå ¥ããå¿ èŠã¯ãããŸãããããäºåºŠãšããªãããšèšãã°ããã®ã§ããã圌ã¯ç¶ããã
圌ãã¯ç§ãã¡å šå¡ãé®æããããšã¯ã§ããŸããã圌ãã¯ãç§ãã¡å šå¡ãé®æããããšã¯ã§ããªãããããªãã®åäŸãã¡ãåŠæ ¡ããç· ãåºãããšãã§ããªãããã¹ãŠã®æ¿åºæ©é¢ãééããããšã¯ã§ããŸããããééãã¹ã建ç©ã®ãªã¹ãã¯ãããããããŸããç§ãã¡ã¯ãäºçŽ°ãªå°å¶åäž»ãç¡èœãªå®åãã¡ã®åœä»€ãééãæ害ãªæ¿çãåãå ¥ããå¿ èŠã¯ãããŸãããç§ãã¡ã¯åçŽã«ãNo, not againããšèšãã°ããã®ã§ãã
ããã€ãã³å€§çµ±é ãç§ãã¡ã¯ããªãã®æ©é¢ã®åœä»€ããå ±åãããããã¯ããŠã³ãžã®åããåãå ¥ããŸããããšããŒã«ã¯èšããŸããã誰ãCDCã®åç§åŠçãªãã¹ã¯ã®çŸ©åã«åŸãã¹ãã§ã¯ãããŸãããã
CDCã®åç§åŠçãªãã¹ã¯ã®çŸ©ååã«ã¯èª°ãåŸãã¹ãã§ã¯ãããŸããããä»å¹Žãåã©ããã¡ã«ãããªã被害ãäžããããšã¯èš±ãããŸããã
çãããç§ãã¡ã¯éšãããŠããã®ã§ããããã¯å ¬è¡è¡çãåœãæãããšããã³ãããã¯ãé£ãæ¢ããããšãšã¯äœã®é¢ä¿ããããŸãããããã¯å·§åŠã«æã®èŸŒãã çµç¹çãªåå Žã§ã人ã ãçç©å µåšã®æ³šå°ã§èªæ®ºã«è¿œã蟌ã¿ãã°ããŒããªã¹ããæ°åå人ãå°çããè¿œãåºããçãæ®ã£ã人ã ãžã®å°å¶ãšæš©åšäž»çŸ©çãªæ¯é ãé²ããããã®ãã®ã§ãã
ããã¯ãäžçã®äžæçŽå¹£ã厩å£ãããçŸãã¡ã®ãã¹ãŠã®é貚è³ç£ãç Žå£ãããã¹ãŠã®æææš©ãã°ããŒããªã¹ãã»ãšãªãŒãã®æã«éçŽãããã圌ãã®èšç»ããéèãªã»ããã®ããã®ã«ããŒã§ããããããããŸããã
ããããäžçäžã®æ¿åºãèªåœæ°ã人質ã«ããŠãã¯ã¯ãã³ã®å²åœéãèŠæ±ããéããããèªç±ããéæŸããããšããŠããçç±ã§ãããã¡ããã次ã®ãå€çš®ããç¹å®ãããã°ãå®å šã«åãæ¶ãããéããããèªç±ãã解ãæŸã€ããã«ãã¯ã¯ãã³ã®å²ãåœãŠãæºããããšãèŠæ±ããŠããŸãã
å
é±ã®éææ¥ã«é
ä¿¡ããããã®ãã¯ãã«ã§ç·æ¥æ§ã®é«ãããããã£ã¹ãã§ãç§ã¯ãã®ãã¹ãŠã説æããŠããŸãã
ã³ãŽã£ããã®è©æ¬ºã®å
šè²ãæ¥éã«è§£æããã€ã€ãããŸããä»åŸããæåŸ
ãã ãããBrighteon.comãšBanned.videoã®ãããªãèŠãŠãããã°ããã¯ã誰ã«ãæããªãçå®ãåŠãã§ãã ããããã®äžççãªå€§è殺ãçãæããããªããNaturalNews.comãèªã¿ãBrighteonã®ç§ã®ãã£ã³ãã«ããã©ããŒããŠãã ããïŒ

ãã®èšäºãæ°ã«å ¥ã£ãããµããŒããããŠã¿ãŸãããïŒ